Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Brazil | Czech | Dominican Republic | Italy | Mexico | Portugal | Slovakia
Approved Indications: None
Known Adverse Events: None
Company: Ache Labs
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Common Cold|Rhinitis|Inflammation
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ACH-NTS-03(02/10) | P3 |
Withdrawn |
Rhinitis|Inflammation|Common Cold |
2012-04-01 |